Yabiladi
China National Pharmaceutical Group Corp (Sinopharm), a Chinese state-owned enterprise, announced on Wednesday that data from late-stage clinical trials for its Covid-19 vaccine are “better than expected”, Reuters reported.
According to the British news agency, Sinopharm has had two of its vaccine candidates move into Phase 3 clinical trials in partner countries, including the United Arab Emirates, Bahrain and Egypt. 50,000 people in total have participated to these trials.
In a statement released on the same, the Chinese pharmaceutical group said that the trials are “nearing their ends”. It is worth noting that Sinopharm did not give details on the “better-than-expected data”, or specify which vaccine candidate the data are generated from, the same source added.
Sinopharm’s vaccine trials are also conducted in Morocco, which signed with the Chinese laboratory two partnership agreements in August.
In Morocco, Dr. Abdelhakim Yahyane, a member of the National Scientific Advisory Committee on Vaccination, told Yabiladi earier this week that vaccine trials in the country “have reached the final phase”.
“We are impatiently awaiting the end of this process, which could probably happen by next week, to then receive the results from the Chinese laboratory”, he concluded.
For the record, Sinopharm agreed to provide Morocco with 10 million doses before the end of the year if results are positive.
LATIFA BABAS
Journalist at Yabiladi.com
